Novo Nordisk Resubmits Awiqli® to FDA for Potential Weekly Diabetes Treatment
Novo Nordisk, the renowned global healthcare company based in Denmark, has recently taken a significant step in the field of diabetes treatment by resubmitting its Biologics License Application (BLA) for Awiqli® (insulin icodec) to the US Food and Drug Administration (FDA). This move is pivotal as it brings the company closer to potentially introducing the first once-weekly basal insulin therapy designed specifically for adults with type 2 diabetes in the United States.
Awiqli® is an investigational product that promises to change the landscape for individuals suffering from type 2 diabetes by significantly simplifying their treatment regimen. If approved, this innovative insulin injection will allow patients to reduce their annual number of injections from 365 to just 52, which could drastically enhance compliance and overall quality of life for diabetes patients.
"With this resubmission, we're closer to offering a new insulin treatment option for people living with type 2 diabetes that, if approved, could reduce their yearly basal insulin injections from 365 to 52," said Anna Windle, PhD, Senior Vice President at Novo Nordisk, during a recent announcement. The importance of this development is underscored by Novo Nordisk’s century-long commitment to advancing diabetes care and the ongoing clinical research supporting Awiqli®.
The decision to resubmit the application follows extensive results from the ONWARDS clinical trial program, which involved nearly 4,000 adults with type 2 diabetes. The ONWARDS program included five randomized, active-controlled, treat-to-target trials aimed at comparing the efficacy of Awiqli® against daily basal insulin. The primary goal of these trials was to assess the change in A1C levels from baseline, which is a critical measure of blood glucose control in diabetic patients.
Awiqli® functions as a novel insulin analogue, uniquely designed to meet the basal insulin needs of patients with just one subcutaneous injection per week. Such a treatment could revolutionize diabetes management by minimizing the burden of daily injections and potentially improving patient adherence. The recent resubmission was prompted by the FDA's action letter received in Q3 of 2024, highlighting the necessity for continued innovation in diabetes care.
While Awiqli® is still pending approval in the US, it has already achieved success in the European Union and 12 other countries, expanding access to what could be a life-changing treatment option for many. Furthermore, Novo Nordisk is actively pursuing regulatory approvals in additional countries, with further decisions anticipated in 2025.
"This resubmission is a testament to our commitment to develop innovative solutions that cater to the evolving needs of diabetes patients worldwide. Our goal is to enhance diabetes management and ultimately improve patient outcomes through scientific advancements and practical solutions like Awiqli®," added Windle.
Novo Nordisk's dedication goes beyond just insulin products; it encompasses a broader vision of transforming diabetes care, from prevention strategies to novel treatment paradigms. With an employment base of around 78,400 people across 80 countries, the company markets its innovative healthcare solutions in approximately 170 countries, cementing its position as a global leader in diabetes care.
The pathway to approval for Awiqli® represents a crucial development in diabetic care and fuels hope for many individuals managing type 2 diabetes. The potential impact of this treatment could lead to fewer injections, improved adherence, and ultimately better health outcomes.
As further regulatory decisions unfold, both patients and healthcare professionals are encouraged to remain informed about the progress of Awiqli® and the developments stemming from Novo Nordisk's decades of expertise in diabetes care. For updates, individuals can explore Novo Nordisk’s official channels including their website and social media platforms.
Awiqli® is an investigational product that promises to change the landscape for individuals suffering from type 2 diabetes by significantly simplifying their treatment regimen. If approved, this innovative insulin injection will allow patients to reduce their annual number of injections from 365 to just 52, which could drastically enhance compliance and overall quality of life for diabetes patients.
"With this resubmission, we're closer to offering a new insulin treatment option for people living with type 2 diabetes that, if approved, could reduce their yearly basal insulin injections from 365 to 52," said Anna Windle, PhD, Senior Vice President at Novo Nordisk, during a recent announcement. The importance of this development is underscored by Novo Nordisk’s century-long commitment to advancing diabetes care and the ongoing clinical research supporting Awiqli®.
The decision to resubmit the application follows extensive results from the ONWARDS clinical trial program, which involved nearly 4,000 adults with type 2 diabetes. The ONWARDS program included five randomized, active-controlled, treat-to-target trials aimed at comparing the efficacy of Awiqli® against daily basal insulin. The primary goal of these trials was to assess the change in A1C levels from baseline, which is a critical measure of blood glucose control in diabetic patients.
Awiqli® functions as a novel insulin analogue, uniquely designed to meet the basal insulin needs of patients with just one subcutaneous injection per week. Such a treatment could revolutionize diabetes management by minimizing the burden of daily injections and potentially improving patient adherence. The recent resubmission was prompted by the FDA's action letter received in Q3 of 2024, highlighting the necessity for continued innovation in diabetes care.
While Awiqli® is still pending approval in the US, it has already achieved success in the European Union and 12 other countries, expanding access to what could be a life-changing treatment option for many. Furthermore, Novo Nordisk is actively pursuing regulatory approvals in additional countries, with further decisions anticipated in 2025.
"This resubmission is a testament to our commitment to develop innovative solutions that cater to the evolving needs of diabetes patients worldwide. Our goal is to enhance diabetes management and ultimately improve patient outcomes through scientific advancements and practical solutions like Awiqli®," added Windle.
Novo Nordisk's dedication goes beyond just insulin products; it encompasses a broader vision of transforming diabetes care, from prevention strategies to novel treatment paradigms. With an employment base of around 78,400 people across 80 countries, the company markets its innovative healthcare solutions in approximately 170 countries, cementing its position as a global leader in diabetes care.
The pathway to approval for Awiqli® represents a crucial development in diabetic care and fuels hope for many individuals managing type 2 diabetes. The potential impact of this treatment could lead to fewer injections, improved adherence, and ultimately better health outcomes.
As further regulatory decisions unfold, both patients and healthcare professionals are encouraged to remain informed about the progress of Awiqli® and the developments stemming from Novo Nordisk's decades of expertise in diabetes care. For updates, individuals can explore Novo Nordisk’s official channels including their website and social media platforms.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.